New Imaging Strategies for Prostate Cancer
Abstract
Imaging prostate cancer could be desirable from the perspective of helping tell where the tumor is, which can also aid the choice of therapeutic approaches and as a means to quantitate the results of therapy. Best would be the availability of low molecular ligands that could be generated with positron containing radionucleotides given their high sensitivity. In this report we describe the development of these new ligands and their improved binding characteristics and our pursuit of structure activity modifications to identify the best ligands for developing as PET radioligands. We identified a number of 2,5 A nucleotide glutamate urea ligands with excellent binding activity for PSMA While these ligands had excellent activity in vitro, they did not demonstrate in vivo binding activity. However, based on their excellent activity we were able to generate other ligands based on the 2,5A structure that were active in vivo with excellent imaging characteristics. We also identified that while PSMA is a feature of the majority of prostate cancers, that those tumors expressing the TMPRSS/ERG fusion gene may have some attenuation in PSMA signal.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2010
- Accession Number
- ADA547550
Entities
People
- Warren Heston